Arena Pharmaceuticals, Inc.
METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR

Abstract:

Provided is a method of determining if an individual is a responder to treatment with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydroc- yclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof.